Calm and Objective, page-15

This article is precisely the kind of early signal we've been waiting for — direct testimony from a carer in the Phase 2b trial of Xanamem showing real-world cognitive improvement. As Dr. Gourlay reminds us, Xanamem is first-in-class, targets cortisol, and is designed to treat the underlying biology of Alzheimer's, not just reduce plaques.

This isn't retail hype. It's not message board speculation. This is a national newspaper article, quoting Actinogen's CEO and a real family seeing results.We're not just talking potential anymore. We're starting to see it in action.